Furthermore, the company will be able to formulate and manufacture new dosage forms.
The expansion includes the addition of four new current good manufacturing practice (cGMP) processing suites and all associated manufacturing support areas.
Avista Pharma’s drug product capabilities will now include encapsulation, high-shear granulation, fluid-bed granulation, drying and coating, tablet compression, and packaging.
In addition, the company’s operations team now supports the formulation and manufacture of dosage forms such as immediate-release tablets and capsules, enteric-release tablets, modified-release, multi-particulate tablets, and capsules.
Other dosage forms include hydrophilic and hydrophobic matrix extended-released tablets, opiate tamper-resistant, modified-release pills, and coated aqueous insoluble active ingredients.
The new manufacturing suites have been designed and monitored to ISO 7 requirements and the expanded support areas meet ISO 8 requirements. This includes a wash and prep area, in addition to clean equipment storage.
Longmont facility general manager Ken Domagalski said: “Expanding our drug product capabilities enables us to better serve our clients as a trusted, effective and innovative partner in all phases of the drug development lifecycle.
“By offering optimised formulation and manufacturing of a wider range of dosage forms, we can now help make more life-preserving medicines a reality.”